IRIS
BARONE, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 920
EU - Europa 413
AS - Asia 173
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 4
Totale 1.521
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 901
CN - Cina 159
FI - Finlandia 69
NL - Olanda 64
IE - Irlanda 63
IT - Italia 59
UA - Ucraina 54
DE - Germania 50
SE - Svezia 28
GB - Regno Unito 24
CA - Canada 19
CI - Costa d'Avorio 11
IN - India 10
EU - Europa 4
SG - Singapore 3
FR - Francia 1
IR - Iran 1
SI - Slovenia 1
Totale 1.521
Salva come PNG Salva come JPEG
Città #
Chandler 170
Jacksonville 100
Ashburn 76
Millbury 73
Princeton 70
Amsterdam 64
Nanjing 59
Boston 39
Nanchang 29
Wilmington 29
Ottawa 19
Beijing 16
Norwalk 15
Seattle 13
Washington 12
Boardman 11
Houston 11
Kunming 10
Naples 9
Napoli 9
Rome 9
Pune 8
Falls Church 7
Jiaxing 7
Shenyang 7
Los Angeles 6
Tianjin 6
Shanghai 5
Changsha 4
Hangzhou 4
Hebei 4
Kronberg 4
Ann Arbor 3
Changchun 3
Dublin 3
Indiana 3
Orange 3
Redmond 3
Campagna 2
Des Moines 2
Lanzhou 2
New York 2
Nürnberg 2
San Mateo 2
Singapore 2
Augusta 1
Bangalore 1
Brusciano 1
Chisago City 1
Guangzhou 1
Islington 1
Ljubljana 1
London 1
Milan 1
Monteriggioni 1
Ospedaletto Euganeo 1
Redwood City 1
Shenzhen 1
Troisdorf 1
Woodbridge 1
Totale 952
Salva come PNG Salva come JPEG
Nome #
Reduced striatal [123I]FP-CIT binding in SCA2 patients without parkinsonism 52
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial 51
Loss of cutaneous large and small fibers in naive and l-dopa-treated PD patients 38
Dopamine mediated responses in 6-OH-DA lesioned rats involve changes of the signal transduction. 37
Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease 35
Amitriptyline as a prophylactic for migraine in children. 33
Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. 33
Behavioural sensitization in 6-OHDA lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB-related and JunD-related proteins 32
Dopa-responsive pseudo-orthostatic tremor in parkinsonism. 32
Freezing of gait and executive functions in patients with Parkinson's disease. 32
Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness as presenting symptoms of PARK-2. 31
Nitrite- and peroxide-dependent oxidation pathways of dopamine: 6-nitrodopamine and 6-hydroxydopamine formation as potential contributory mechanisms of oxidative stress- and nitric oxide-induced neurotoxicity in neuronal degeneration 30
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. 30
Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: an FP-CIT SPECT study. 30
The status of dopamine nerve terminals in Parkinson\'s disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. 29
A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. 28
A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. 27
Is arginine test a reliable tool for differential diagnosis of multiple system atrophy? 27
No evidence of association between CAG expansions and essential tremor in a large cohort of italian patients 26
Depression rating scales in Parkinson's disease: critique and recommendations. 26
Dopamine agonist-based strategies in the treatment of Parkinson's disease. 26
Dopamine receptor agonists and depression in Parkinson's disease. 26
Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. 26
Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. 24
Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. 24
Diffusion-weighted imaging in multiple system atrophy: a comparison between clinical subtypes. 24
Apoptotic mechanisms in mutant LRRK2-mediated cell death. 23
Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT. 23
Neurotransmission in Parkinson's disease: beyond dopamine. 23
Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia. 23
Pergolide monotherapy in the treatment of early PD. A randomized, controlled study. 22
Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. 22
Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. 22
Linkage exclusion in Italian families with hereditary essential tremor. 22
Headache in children, an epidemiological study. 21
Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. 21
No evidence of association between CAG expansions and essential tremor in a large cohort of italian patients 20
The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms 20
The PRIAMO study: background, methods and recruitment. 20
Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. 20
Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. 18
Red flags for multiple system atrophy. 18
Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. 18
Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. 18
PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. 17
International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. 17
Clinical and neurological abnormalities in adult celiac disease. 17
Vestibular impairment and adaptive postural imbalance in parkinsonian patients with lateral trunk flexion 17
Nitric oxide-hemoglobin interaction: a new biochemical hypothesis for signal changes in fMRI 17
MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. 16
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). 16
Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. 16
Perspectives on recent advances in the understanding and treatment of Parkinson's disease. 16
RNA analysis of consensus sequence splicing mutations: implications for the diagnosis of Wilson disease. 16
Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. 16
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. 16
HOMER1 promoter analysis in parkinson's disease: association study with psychotic symptoms 15
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. 14
The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. 14
How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. 13
Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. 13
HOMER1 promoter analysis in Parkinson's disease: association study with psychotic symptoms. 13
Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease. 12
The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. 12
null 12
Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test 11
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. 11
Subclinical sensory abnormalities in unaffected PINK1 heterozygotes. 10
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. 10
The FRAGAMP study: environmental and genetic factors inParkinson's disease, methods and clinical features. 10
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. 9
Totale 1.559
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.934
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.934
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192 0 0 0 0 0 0 0 0 0 0 0 2
2019/2020174 71 5 11 0 11 0 1 1 1 9 17 47
2020/2021146 1 11 19 11 11 45 11 2 13 2 19 1
2021/2022319 3 0 0 4 0 9 1 12 67 12 52 159
2022/2023410 73 35 17 25 46 33 0 38 57 66 16 4
2023/2024236 7 38 32 35 27 53 2 32 0 10 0 0
Totale 1.559